Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models

by Koen Degeling, Maarten J. IJzerman, Miriam Koopman, Hendrik Koffijberg
Published 2017-12-01

Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences.

by Sander Brinkhof, Harry J M Groen, Sabine S Siesling, Maarten J IJzerman
Published 2017-01-01

Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval.

by Annemieke Witteveen, Annemiek B G Kwast, Gabe S Sonke, Maarten J IJzerman, Sabine Siesling
Published 2015-01-01

The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care

by Michelle M. A. Kip, Hendrik Koffijberg, Marco J. Moesker, Maarten J. IJzerman, Ron Kusters
Published 2017-08-01

Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility

by A. M. Sofie Berghuis, Hendrik Koffijberg, Jai Prakash, Leon W. M. M. Terstappen, Maarten J. IJzerman
Published 2017-02-01

Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review

by Koen Degeling, Amanda Pereira-Salgado, Niall M. Corcoran, Paul C. Boutros, Peter Kuhn, Maarten J. IJzerman
Published 2021-05-01

A scoping review of studies using observational data to optimise dynamic treatment regimens

by Robert K. Mahar, Myra B. McGuinness, Bibhas Chakraborty, John B. Carlin, Maarten J. IJzerman, Julie A. Simpson
Published 2021-02-01

Understanding the adoption and use of point-of-care tests in Dutch general practices using multi-criteria decision analysis

by Michelle M. A. Kip, J. Marjan Hummel, Elra B. Eppink, Hendrik Koffijberg, Rogier M. Hopstaken, Maarten J. IJzerman, Ron Kusters
Published 2019-01-01

Whole genome sequencing in oncology: using scenario drafting to explore future developments

by Michiel van de Ven, Martijn J. H. G. Simons, Hendrik Koffijberg, Manuela A. Joore, Maarten J. IJzerman, Valesca P. Retèl, Wim H. van Harten
Published 2021-05-01

Involving Patients in Weighting Benefits and Harms of Treatment in Parkinson's Disease.

by Marieke G M Weernink, Janine A van Til, Jeroen P P van Vugt, Kris L L Movig, Catharina G M Groothuis-Oudshoorn, Maarten J IJzerman
Published 2016-01-01

Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late

by Maarten J. IJzerman, Jasper de Boer, Arun Azad, Koen Degeling, Joel Geoghegan, Chelsee Hewitt, Frédéric Hollande, Belinda Lee, Yat Ho To, Richard W. Tothill, Gavin Wright, Jeanne Tie, Sarah-Jane Dawson
Published 2021-01-01

Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherl...

by Michelle M. A. Kip, Jos A. van Oers, Arezoo Shajiei, Albertus Beishuizen, A. M. Sofie Berghuis, Armand R. Girbes, Evelien de Jong, Dylan W. de Lange, Maarten W. N. Nijsten, Maarten J. IJzerman, Hendrik Koffijberg, Ron Kusters
Published 2018-11-01

Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review

by Michelle M. A. Kip, Gillian Currie, Deborah A. Marshall, Luiza Grazziotin Lago, Marinka Twilt, Sebastiaan J. Vastert, Joost F. Swart, Nico Wulffraat, Rae S. M. Yeung, Susanne M. Benseler, Maarten J. IJzerman, on behalf of the UCAN CAN-DU Health Economics Working Group
Published 2019-05-01